- Home
- CHPG vs ADAG Comparison
CHPG vs ADAG Comparison
Compare CHPG & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPG
- ADAG
- Stock Information
- Founded
- CHPG 2024
- ADAG 2011
- Country
- CHPG United States
- ADAG China
- Employees
- CHPG N/A
- ADAG N/A
- Industry
- CHPG
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- CHPG
- ADAG Health Care
- Exchange
- CHPG Nasdaq
- ADAG Nasdaq
- Market Cap
- CHPG 101.2M
- ADAG 84.4M
- IPO Year
- CHPG N/A
- ADAG 2021
- Fundamental
- Price
- CHPG $10.16
- ADAG $1.90
- Analyst Decision
- CHPG
- ADAG Strong Buy
- Analyst Count
- CHPG 0
- ADAG 3
- Target Price
- CHPG N/A
- ADAG $7.67
- AVG Volume (30 Days)
- CHPG 10.4K
- ADAG 80.7K
- Earning Date
- CHPG 07-23-2025
- ADAG 08-12-2025
- Dividend Yield
- CHPG N/A
- ADAG N/A
- EPS Growth
- CHPG N/A
- ADAG N/A
- EPS
- CHPG N/A
- ADAG N/A
- Revenue
- CHPG N/A
- ADAG $103,204.00
- Revenue This Year
- CHPG N/A
- ADAG $7,411.34
- Revenue Next Year
- CHPG N/A
- ADAG $28.29
- P/E Ratio
- CHPG N/A
- ADAG N/A
- Revenue Growth
- CHPG N/A
- ADAG N/A
- 52 Week Low
- CHPG $9.81
- ADAG $1.30
- 52 Week High
- CHPG $10.24
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- CHPG N/A
- ADAG 52.53
- Support Level
- CHPG N/A
- ADAG $1.78
- Resistance Level
- CHPG N/A
- ADAG $1.99
- Average True Range (ATR)
- CHPG 0.00
- ADAG 0.19
- MACD
- CHPG 0.00
- ADAG 0.03
- Stochastic Oscillator
- CHPG 0.00
- ADAG 72.85
About CHPG ChampionsGate Acquisition Corporation Class A Ordinary Share
Championsgate Acquisition Corp is a blank check company.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.